<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Preoperative portal vein embolization</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Preoperative portal vein embolization</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Preoperative portal vein embolization</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Senthil Kumar, MS, FRCS (Ed), FRCS (Gen Surg), CCT (UK)</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stanley W Ashley, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2772347224"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Liver resection has evolved into an oncologically effective treatment for primary hepatic malignancies (eg, hepatocellular carcinoma, cholangiocarcinoma) and for the treatment of metastatic liver tumors (eg, colorectal carcinoma, neuroendocrine tumor). In many clinical situations, liver resection, when possible, provides the best survival outcomes. However, the limits of liver resection are determined by the probability of leaving behind a safe volume of functional liver that has an adequate vascular inflow, venous outflow, and biliary drainage. </p><p>The generally accepted safe minimum threshold for the future liver remnant (FLR) varies from 20 to 25 percent for a normal liver to &gt;40 percent for a cirrhotic liver [<a href="#rid1">1-3</a>]. If the FLR volume is deemed unsafe or marginal, adjunctive or alternative methods to ensure an adequate postresection liver volume may include a staged resection, the associating liver partition and portal vein ligation for staged hepatectomy procedure, a hybrid procedure that combines liver resection with ablation techniques, and portal vein occlusion techniques such as preoperative portal vein ligation (PVL) or preoperative portal vein embolization (PVE).<strong> </strong></p><p>Preoperative PVE is the elective obliteration of portal blood flow to a selected portion of the liver a few weeks prior to planned major liver resection. PVE initiates hypertrophy of the anticipated FLR. Preoperative PVE is a valuable adjunct to major liver resection, particularly for right-sided tumors, and it may allow a more extensive resection or staged bilateral resections [<a href="#rid4">4-10</a>]. The indications, contraindications, and techniques for PVE and a comparison of PVE with other techniques are reviewed here. (See  <a class="medical medical_review" href="/z/d/html/15094.html" rel="external">"Overview of hepatic resection"</a> and  <a class="medical medical_review" href="/z/d/html/88319.html" rel="external">"Open hepatic resection techniques"</a>.)</p><p class="headingAnchor" id="H3767948694"><span class="h1">LIVER VOLUME AND FUNCTIONAL ASSESSMENT</span><span class="headingEndMark"> — </span>In evaluating the need for preoperative portal vein embolization (PVE), the standardized future liver remnant (FLR) needs to be determined. (See  <a class="medical medical_review" href="/z/d/html/15094.html" rel="external">"Overview of hepatic resection", section on 'Preoperative imaging'</a>.)</p><p>A clear understanding and application of appropriate estimation of the volume and function of the liver is an important aspect of patient selection. Many methods are in clinical use, and each has advantages and disadvantages. There is always a discrepancy between the measured or estimated volume and the actual weight, as demonstrated from graft weight measurements in living donor liver transplantation. The same applies to functional assessment as well. </p><p>The reasons for such discrepancies include: </p><p class="bulletIndent1"><span class="glyph">●</span>The assumption that the density of liver is 1.0 (ie, that the liver weight in grams = volume in mL). Although this is practically useful, the liver parenchyma is actually denser, and the conversion factor may be greater than 1.0. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The assumption that liver parenchyma is homogenous. This is not true, as the proportion of the vasculobiliary components of the liver in relation to the hepatocellular mass is variable. Moreover, in patients with tumors, the size, number, and distribution will affect volumetry.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In terms of function, the left lobe is marginally inferior to the right lobe even when corrected for volume [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H2438396322"><span class="h2">Liver volumetry</span><span class="headingEndMark"> — </span>Liver volume can be measured using manual or software-assisted methods using a number of imaging techniques such as computed tomography (CT), magnetic resonance (MR), or scintigraphy [<a href="#rid3">3,12,13</a>]. Alternatively, liver volume may be estimated using validated formulas that use a combination of age, sex, and anthropometric parameters such as height, weight, and body surface area [<a href="#rid14">14</a>]. Approximately 16 formulas are in use to derive estimated total liver volume (eTLV). The standardized functional liver remnant (sFLR) is the ratio between volumetrically measured FLR and the derived eTLV. Another method is the measured functional liver remnant (mFLR) in which both the remnant volume and the total liver volume are measured by CT volumetry. FLR in this method is usually expressed as a ratio of remnant volume to the total functional liver volume (total liver volume-tumor volume). </p><p>The chosen technique for measuring FLR depends upon the local availability of expertise and software. The results and principles of application are similar as long as the same technique is followed for both pre- and postembolization estimates. Thus, in the discussions below, we refer to FLR generically.</p><p class="headingAnchor" id="H2475090291"><span class="h2">Functional liver studies</span><span class="headingEndMark"> — </span>There is evidence from radionuclide studies that the increase in the functional capacity of the liver after preoperative PVE may be more than the increase in volumes that are measured using CT volumetry [<a href="#rid15">15,16</a>]. The increase in functional capacity can be measured by one of two radionuclide techniques: <sup>99m</sup>Tc-labelled galactosyl-human serum albumin (<sup>99m</sup>Tc-GSA) or <sup>99m</sup>Tc-labelled mebrofenin hepatobiliary scintigraphy with single-photon emission computed tomography (SPECT) [<a href="#rid16">16</a>]. The <sup>99m</sup>Tc-GSA technique relies on the binding of the tracer to specific receptors expressed on functional hepatocytes, while the labeled mebrofenin with SPECT is based on the uptake and excretion kinetics of mebrofenin by the hepatocytes. </p><p>Other techniques used for functional assessment include <a class="drug drug_general" data-topicid="8982" href="/z/d/drug information/8982.html" rel="external">indocyanine green</a> retention at 15 minutes (ICG-15), the <sup>13</sup>C-Methacetin breath test (LiMax test), and contrast-enhanced MR imaging using gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (gadolinium-EOB-DTPA) [<a href="#rid16">16,17</a>]. ICG-15 is an accepted parameter for functional capacity of liver. A level &lt;10 percent is considered normal, although some labs quote a slightly higher value of up to 14 percent.</p><p class="headingAnchor" id="H2425761269"><span class="h1">MECHANISM AND PHYSIOLOGY</span><span class="headingEndMark"> — </span>Preoperative portal vein embolization (PVE) is the elective obliteration of portal blood flow to a selected portion of the liver a few weeks prior to planned major liver resection, with the intention of eliciting a hypertrophic physiologic response in the nonembolized portion. The purpose is to augment the volume and potentially the function of the future liver remnant (FLR) to a safe threshold and minimize the risk of post-hepatectomy liver failure and related complications such as sepsis, multiorgan failure, and mortality. Preoperative PVE usually takes the form of a right PVE, performed in preparation of a planned major right-sided resection such as an extended right hepatectomy (in a normal liver) or a right hepatectomy (in a cirrhotic liver). Very rarely, a left preoperative PVE may be indicated before a left-sided resection. </p><p>The sequela of selective portal vein occlusion, ipsilateral atrophy with contralateral hypertrophy, was first demonstrated in a rabbit model in 1920 [<a href="#rid18">18</a>]. Forty years later, portal vein ligation was used as a part of a two-staged hepatectomy [<a href="#rid19">19</a>]. However, the first PVE to facilitate safe liver resection was not reported until 1984 [<a href="#rid20">20</a>]. The effectiveness of PVE has been documented for a variety of different cancers and in patients with varying clinical profiles. </p><p>The increase in liver volume is due to clonal expansion of the number of hepatocytes (hyperplasia) and not by an increase in size of existing hepatocytes (hypertrophy). Preoperative PVE causes immediate redistribution of portal blood flow to the nonembolized liver segments, which returns toward baseline levels by 11 days [<a href="#rid21">21</a>]. The increased flow stimulates a regenerative response. The arterial flow to the nonembolized segments is reduced only marginally [<a href="#rid22">22</a>]. Key factors involved in the regenerative response include hepatocyte growth factor, epidermal growth factor, transforming growth factor alpha, insulin, noradrenaline, and cytokines such as interleukin-6 and tumor necrosis factor-alpha. The genes for some of these may be expressed as quickly as 30 minutes after hepatocyte injury [<a href="#rid23">23</a>]. </p><p>At four to six weeks after PVE, the expected increase of standardized FLR ranges from 8 to 13 percent, although some studies have reported higher rates [<a href="#rid5">5,24,25</a>]. When expressed as a percentage augmentation from baseline FLR (ie, without PVE), this corresponds to a 40 to 62 percent increase [<a href="#rid26">26</a>]. (See <a class="local">'Liver volume and functional assessment'</a> above.)</p><p>In a retrospective study of 79 patients, four radiological features were identified as adverse factors for remnant hypertrophy after PVE [<a href="#rid27">27</a>]. These included: variant portal venous anatomy at the hilum (as against the standard bifurcation); presence of proximal small branches from the right anterior and posterior sectoral veins; presence of tumor thrombus in the right portal vein; and presence of transient parenchymal enhancement in the arterial phase. The absence of all these features predicted a favorable outcome (50 percent remnant hypertrophy), while the presence of any one of the features almost halved the remnant hypertrophy. Although promising, these features need validation from larger studies before they can be incorporated into selection algorithms. </p><p>The kinetics of liver regeneration following preoperative PVE are slower and of a different nature compared with those following liver resection. The rate of liver regeneration in normal liver peaks approximately two weeks after PVE at 12 to 21 cm<sup>3</sup>/day, and plateaus by three weeks, with a rate at one month of approximately 6 to 11 cm<sup>3</sup>/day [<a href="#rid4">4</a>]. However, studies have documented a continued growth of the liver up to one year post-PVE, with only about 25 percent of the total possible growth occurring in the first month, 50 percent by three months, and 75 percent by about eight months [<a href="#rid28">28</a>]. Factors that adversely affect regeneration after PVE include increasing age, male sex, a high initial FLR volume, diabetes, cholestasis (with or without biliary drainage), and parenchymal liver disease [<a href="#rid5">5,29,30</a>]. Some [<a href="#rid31">31,32</a>], but not all, studies [<a href="#rid10">10,33,34</a>] have found a detrimental effect of prolonged pre-PVE chemotherapy on the volume gain.</p><p>The growth rate after PVE as well as the degree of hypertrophy (DH), which is the difference between the FLR percentage before and after PVE, have been shown to be important predictors of post-hepatectomy liver failure [<a href="#rid15">15,25,35</a>]. The FLR percentage is the ratio of the FLR volume measured with computed tomography (CT) volumetry (numerator) and the functional liver volume (total liver volume-tumor volume) (denominator).</p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1"><span class="glyph">●</span>DH = [FLR/(TLV-tumor volume)]<sub>post-PVE</sub> - [FLR/(TLV-tumor volume)]<sub>pre-PVE</sub> </p></div></div><p></p><p class="bulletIndent1">Where:</p><p class="bulletIndent2">DH: degree of hypertrophy</p><p class="bulletIndent2">TLV: total liver volume</p><p class="bulletIndent2">FLR: future liver remnant</p><p class="bulletIndent2">PVE: portal vein embolization</p><p></p><p>A DH &gt;5 percent in normal liver and &gt;10 percent in cirrhotic liver is considered a marker of adequate regenerative capacity and hence carries a reduced risk of postresection liver failure [<a href="#rid10">10,36</a>]. </p><p>The kinetic growth rate (KGR) is the DH/week. A KGR &gt;2 to 2.66 percent/week is considered to be a marker of a safe hypertrophic response that correlates with reduced rates of post-hepatectomy liver failure and major complications [<a href="#rid25">25,35,37</a>]. </p><p class="headingAnchor" id="H2472470834"><span class="h1">PATIENT SELECTION</span><span class="headingEndMark"> — </span>Based upon observational studies demonstrating improved survival and reduced rates of postoperative liver failure following extended hepatic resections in those who have undergone portal vein embolization (PVE) [<a href="#rid38">38-40</a>], in the absence of severe liver dysfunction, we suggest an attempt at PVE in most patients with a marginal predicted future liver remnant (FLR; ie, &lt;20 percent in patients with a normal liver, &lt;30 percent for patients with nonalcoholic steatohepatitis, &lt;40 percent in patients with cirrhosis) [<a href="#rid41">41</a>]. (See <a class="local">'Functional liver remnant thresholds'</a> below.)</p><p>However, the probability of successful liver enlargement decreases as the volume of FLR that is needed increases. In addition, as the severity of underlying liver disease increases, the likelihood that the liver will actually enlarge in response to PVE decreases [<a href="#rid42">42</a>]. Systemic disease such as diabetes may additionally limit liver hypertrophy and the success of the procedure. PVE appears to be most beneficial for patients with steatohepatitis with no metabolic dysfunction. </p><p class="headingAnchor" id="H2097587161"><span class="h2">Benefits and risks</span><span class="headingEndMark"> — </span>There are at least five potential benefits to preoperative PVE [<a href="#rid4">4</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Postresection morbidity is diminished, as evidenced by minimal reductions in postresection liver function [<a href="#rid43">43</a>], and patients have fewer pulmonary complications and decreased length of intensive care unit and inpatient hospitalization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who were initially unresectable because of insufficient remaining normal hepatic parenchyma can undergo resection for potential cure. In one study involving resection of extensive colorectal metastases, the rate of curative resection was increased from 46 to 79 percent following preoperative PVE [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subclinical disease or rapid progression may be detected prior to definitive surgery on postembolization imaging studies, thus preventing an unnecessary operation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The volume of remaining liver standardized to patient size (body surface area) predicts mortality after resection in cirrhotics, and the increase in functional liver volume achieved by preoperative PVE may decrease mortality of resection in these patients [<a href="#rid4">4,43,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The absence of compensatory hypertrophy in response to successful preoperative PVE indicates the patient is not suitable for major hepatic resection.</p><p></p><p>Risks specific to preoperative PVE include portal vein thrombosis, liver infarction and necrosis, and portal hypertension [<a href="#rid45">45</a>]. Some reports have shown accelerated tumor growth in the liver after PVE. However, tumor growth is not seen when all of the tumor-bearing areas of the liver are embolized [<a href="#rid10">10</a>]. </p><p>Other risks related to percutaneous transhepatic access are similar to those of any percutaneous intervention, such as bleeding, infection, pseudoaneurysm, and arteriovenous fistula [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/15202.html" rel="external">"Access-related complications of percutaneous access for diagnostic or interventional procedures"</a>.)</p><p class="headingAnchor" id="H305517573"><span class="h2">Functional liver remnant thresholds</span><span class="headingEndMark"> — </span>Preoperative PVE is indicated when the FLR is deemed inadequate or unsafe <strong>and</strong> there is a reasonable prospect of an increase in the volume of FLR after preoperative PVE to an extent that would shift the expected FLR to a safe level that would permit liver resection. Although there is no universal consensus on what would be an ideal minimum FLR, most experts agree on the following broad practical guidelines for considering PVE [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In an otherwise normal liver (this is a rare situation in clinical practice): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A standardized FLR of &lt;20 percent, or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FLR to body weight ratio of &lt;0.5 percent (Truant criterion) [<a href="#rid46">46</a>]<sup> </sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the presence of significant steatosis/cholestasis/chemotherapy-associated steatohepatitis/chronic hepatitis: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A standardized FLR of &lt;30 percent [<a href="#rid47">47</a>], or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FLR to body weight ratio of &lt;0.8 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the presence of cirrhosis (Child A): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A standardized FLR of &lt;40 percent [<a href="#rid48">48</a>], or </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FLR to body weight ratio &lt;1.4 percent [<a href="#rid49">49</a>], or </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FLR of &lt;250 mL/m<sup>2</sup> (Shirabe criterion) [<a href="#rid44">44</a>]</p><p></p><p>However, a wide variation exists in the cutoffs used depending upon a number of other factors, such as age, diabetes, background liver disease, and individual surgeon experience. The evolution of liver resection has lowered these thresholds. In the early experience, the FLR threshold in a normal liver for PVE in the treatment of cholangiocarcinoma was 40 percent. In the early 2000s, the recommended minimum standardized FLR was lowered to 25 percent [<a href="#rid12">12,50</a>]. Further studies supported a threshold as low as 20 percent [<a href="#rid10">10,51,52</a>]. A consensus conference on resectability of liver metastasis in 2006 and another on multidisciplinary management of hepatocellular carcinoma in 2010 have endorsed the lower threshold of 20 percent minimum FLR in normal functioning livers [<a href="#rid1">1,2</a>]. </p><p>Another point that should be kept in mind, particularly in a setting of hilar cholangiocarcinoma, is that PVE commits the surgeon to the ipsilateral resection. This often means an extended right hepatectomy. This places a significant constraint on the flexibility of operative decision making in patients with hilar cholangiocarcinoma who have had a PVE. </p><p>In cirrhotic livers, in addition to the Child-Pugh status, <a class="drug drug_general" data-topicid="8982" href="/z/d/drug information/8982.html" rel="external">indocyanine green</a> retention at 15 minutes (ICG-R15) is often factored into treatment algorithms. As an example, a protocol from China considers Child B or Child C status to be contraindications to major hepatic resection (&gt;3 segments), and also an ICG-R15 of &gt;20 percent [<a href="#rid53">53</a>]. But for patients with Child A cirrhosis, if the ICG-R15 is &lt;20 percent, then a minimum FLR of 30 percent is required for a right hepatectomy and 35 percent for an extended right hepatectomy. Patients with FLRs below these thresholds are considered for PVE. Another major cancer center protocol in the United States uses a higher FLR threshold for hepatic resection in patients with Child A cirrhosis. If ICG-R15 is normal (&lt;10 percent), then a 40 percent remnant is acceptable, while a 50 percent FLR is required if ICG-R15 is between 10 and 20 percent [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H1320620067"><span class="h2">Contraindications</span><span class="headingEndMark"> — </span>Contraindications to preoperative PVE include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient unfit for major resective surgery</p><p class="bulletIndent2"><span class="glyph">•</span>Significant cardiopulmonary comorbidities</p><p class="bulletIndent2"><span class="glyph">•</span>Poor performance status</p><p class="bulletIndent2"><span class="glyph">•</span>Child C status (most Child B patients as well)</p><p class="bulletIndent2"><span class="glyph">•</span>Severe portal hypertension</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patient unfit for intervention (may be temporary)</p><p class="bulletIndent2"><span class="glyph">•</span>Uncorrectable coagulopathy</p><p class="bulletIndent2"><span class="glyph">•</span>Overt sepsis</p><p class="bulletIndent2"><span class="glyph">•</span>Renal failure needing dialysis </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Technical issues</p><p class="bulletIndent2"><span class="glyph">•</span>Lack of portal vein bifurcation</p><p class="bulletIndent2"><span class="glyph">•</span>Lack of intrahepatic portal vein (Abernathy malformation)</p><p class="bulletIndent2"><span class="glyph">•</span>Complete tumor thrombosis of the right portal vein</p><p class="bulletIndent2"><span class="glyph">•</span>Tumor thrombus extending into the FLR</p><p class="bulletIndent2"><span class="glyph">•</span>Tumor precluding safe transhepatic access (transsplenic access may be an alternative)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disease that is too extensive </p><p class="bulletIndent2"><span class="glyph">•</span>Extrahepatic disease precluding curative treatment </p><p class="bulletIndent2"><span class="glyph">•</span>Unlikely to achieve margin negative or R0 resection status in view of extensive disease in FLR</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate predicted FLR</p><p class="bulletIndent2"><span class="glyph">•</span>Baseline FLR so low that it is unlikely PVE would achieve an adequate FLR (this is usually an issue only in patients with chronic liver disease)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bilirubin &gt;5 mg/dL (85 micromol/L) is a relative contraindication</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biliary obstruction </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ascites</p><p></p><p class="headingAnchor" id="H3112775647"><span class="h1">TECHNIQUES</span></p><p class="headingAnchor" id="H3215056952"><span class="h2">Procedure</span><span class="headingEndMark"> — </span>Preoperative portal vein embolization (PVE) is usually performed under conscious sedation and local anesthesia, typically via a percutaneous approach in an interventional suite [<a href="#rid54">54,55</a>]. It can also be performed using an open approach, which is accomplished by cannulating the ileocolic vein at laparotomy, which requires a cooperative effort by the surgeon and interventional radiologist. Although an open approach was the original approach for PVE, it is rarely indicated, but may be used if laparotomy is indicated for another purpose, such as resection of a primary tumor in the colon. </p><p>Percutaneous PVE can be accomplished using a transhepatic or transjugular route. A transsplenic approach has also been reported for PVE in patients in whom multiple tumors precluded a safe trajectory of transhepatic puncture [<a href="#rid56">56</a>]. Direct transhepatic puncture of the portal vein under image guidance is the most commonly performed technique [<a href="#rid5">5</a>]. There are two approaches, the ipsilateral (same side as the tumor/intended resection) and contralateral approach, depending upon which portal vein is punctured [<a href="#rid57">57</a>]. The contralateral approach, first described in 1986, is technically easier but risks injury to the future liver remnant (FLR) [<a href="#rid58">58</a>]. The ipsilateral approach, initially described later in 1996, is more difficult but has become the favored approach [<a href="#rid59">59</a>]. (See <a class="local">'Disease-specific outcomes'</a> below.)</p><p>A variety of embolization agents have been used and include polyvinyl alcohol (PVA), ethiodized oil, absolute alcohol, fibrin, <a class="drug drug_general" data-topicid="10330" href="/z/d/drug information/10330.html" rel="external">sodium tetradecyl sulfate</a> foam, cyanoacrylate glue, gelatin, metallic spherical particles, and coils [<a href="#rid57">57,60</a>]. Absolute alcohol, although very effective, may cause severe inflammation and has fallen out of favor. Cyanoacrylate causes more effective and long-lasting occlusion compared with thrombin or gelfoam. PVA with coils also produces excellent occlusion with minimal reaction [<a href="#rid4">4</a>]. In general, PVE with small spherical particles is more effective (69 percent increase) than large, nonspherical particles (46 percent increase) [<a href="#rid61">61</a>]. The<strong> </strong>choice depends on the local expertise, availability, and cost. </p><p class="headingAnchor" id="H2881503223"><span class="h2">Adjunctive techniques</span></p><p class="headingAnchor" id="H2248989950"><span class="h3">Sequential TACE-PVE</span><span class="headingEndMark"> — </span>There are potential benefits for performing a transarterial chemoembolization (TACE) before a PVE, especially in the setting of hepatocellular carcinoma (HCC), which is dependent on arterial blood supply. TACE will starve the tumor, and this may prevent interval progression of tumor post-PVE. The inflammatory response to TACE may also contribute to the regenerative response to PVE [<a href="#rid22">22</a>]. In addition, PVE alone might augment tumor blood flow due to the arterial buffer response. However, TACE can obliterate arterioportal shunts, which may cause an escape phenomenon blunting the effect of a PVE [<a href="#rid62">62</a>].</p><p>A number of studies have now supported the view that sequential TACE followed by PVE not only causes a greater and quicker increase in the FLR but also translates to a higher complete tumor necrosis rate and increase in recurrence-free and overall survival in HCC [<a href="#rid7">7,63-66</a>]. PVE can be performed one to two weeks after TACE [<a href="#rid63">63</a>]. For optimal effect in large HCCs that may derive additional blood supply from a segment IV artery or inferior phrenic artery, these vessels may also need to be embolized. (See  <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">"Surgical resection of hepatocellular carcinoma"</a>.)</p><p class="headingAnchor" id="H289717221"><span class="h3">Concomitant segmental arterial ligation and PVE</span><span class="headingEndMark"> — </span>An intraoperative technique pioneered by the French called associating portal embolization and arterial ligation (APEAL) combines right PVE and ligation of a segmental branch of the right hepatic artery (anterior or posterior segmental) along with ligation of Glissonian pedicles to segment IVb  (<a class="graphic graphic_figure graphicRef81897" href="/z/d/graphic/81897.html" rel="external">figure 1</a>) [<a href="#rid67">67</a>]. This technique evolved in the context of a staged procedure for multiple colorectal liver metastases. The first stage consisted of resection of the colorectal primary, clearance of any tumor in the FLR by nonanatomic resection or ablation, and the APEAL procedure. The second stage that was performed after a median of 45 days consisted of an extended right hepatectomy. Median FLR hypertrophy rates of 104 percent at seven days and 134 percent at 30 days have been reported [<a href="#rid67">67</a>]. The attractive aspects of the APEAL procedure are the augmented FLR hypertrophy over and above those observed after conventional PVE and the reduced morbidity and mortality compared with the associating liver partition and portal vein ligation for staged hepatectomy procedure [<a href="#rid67">67</a>]. (See <a class="local">'PVE versus the ALPPS procedure'</a> below.)</p><p class="headingAnchor" id="H1807735676"><span class="h3">Other techniques</span></p><p class="bulletIndent1"><span class="glyph">●</span>Sequential PVE and hepatic vein embolization (PVE-HVE) – Hepatic vein embolization (HVE) after PVE may further increase FLR hypertrophy. It may also improve the development of venous collaterals in the FLR [<a href="#rid68">68,69</a>]. PVE-HVE is usually used as a salvage option when PVE alone fails to achieve adequate FLR hypertrophy. Some centers elect to combine the procedures simultaneously in a single setting and have reported good oncological outcomes [<a href="#rid70">70</a>]. When PVE is combined with HVE, the technique has been called liver venous deprivation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PVE with stem cell transplantation – Bone marrow-derived progenitor cells (CD 133<sup>+ </sup>cells) play a role in repopulation and regeneration of the liver [<a href="#rid71">71</a>]. Infusing these cells into the FLR soon after PVE has been shown to result in a greater and quicker FLR hypertrophy without increasing the complication rate [<a href="#rid72">72-74</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Branched chain amino acid supplementation – There is evidence from a small randomized trial that branched chain amino acid supplementation with PVE increases FLR function [<a href="#rid75">75</a>]. Although the evidence is limited, this may be a practical, simple, and safe adjunct in patients undergoing PVE. </p><p></p><p class="headingAnchor" id="H1557659504"><span class="h3">Experimental techniques</span><span class="headingEndMark"> — </span>Experimental variants of PVE, none of which has been clinically tested, include Madoff's transarterial PVE, Smits's trans-sinusoidal PVE, and Lainas's reversible PVE [<a href="#rid8">8,76</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Madoff's transarterial PVE involves a slow microcatheter infusion of a mixture of iodized oil and absolute alcohol (3:1 ratio) as the embolic medium via the lobar branches of the hepatic artery, which is supposed to reach the portal system through peribiliary plexus. The authors claim a twofold advantage in hypertrophy volumes based on a small series in pigs [<a href="#rid77">77</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Smits's trans-sinusoidal PVE involves injecting a low-viscosity medium into the target hepatic vein while wedged. This relies on reflux of the medium into the portal vein via the sinusoids [<a href="#rid78">78</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reversible PVE, as the name implies, involves employing a specific agent such as powdered gelatin sponge, the embolic effect of which is temporary. The small population that might benefit from this technical variant are those who do not undergo resection for various reasons post-PVE [<a href="#rid79">79</a>]. Using this technique, animal studies have widely variable results as to the degree of FLR hypertrophy.</p><p></p><p class="headingAnchor" id="H3593641256"><span class="h1">AREAS OF CONTROVERSY</span></p><p class="headingAnchor" id="H421378028"><span class="h2">Timing of resection after PVE</span><span class="headingEndMark"> — </span>The timing of hepatic resection following preoperative portal vein embolization (PVE) is a balance between the risk of tumor progression and the benefit of more gain in liver volume with passing time. In general, hepatic surgeons wait for three to six weeks post-PVE before undertaking resection [<a href="#rid10">10,80,81</a>]. </p><p>Volumetric assessment of the liver volume using computed tomography or magnetic resonance imaging is performed before PVE and repeated four weeks after PVE to assess the extent of liver hypertrophy prior to undertaking surgery [<a href="#rid45">45,50</a>]. In patients found to have an insufficient future liver remnant (FLR), the study scan can be repeated after a further three to four weeks to assess further for hypertrophy. (See <a class="local">'Liver volume and functional assessment'</a> above.)</p><p>The increase in liver function outpaces the increase in volume, which always lags behind. Although the rate of growth peaks early and tends to plateau at approximately three weeks, the volume gain at one month is only approximately 25 percent of the total possible volume gain. The liver continues to increase in volume as long as one year after preoperative PVE. (See <a class="local">'Mechanism and physiology'</a> above.)</p><p class="headingAnchor" id="H3786205184"><span class="h2">Extended PVE</span><span class="headingEndMark"> — </span>Right PVE is often performed when an intended right trisectionectomy is planned  (<a class="graphic graphic_figure graphicRef66282" href="/z/d/graphic/66282.html" rel="external">figure 2</a>). Standard right PVE will result in segment IV hypertrophy (as well as hypertrophy of the left lateral segments)  (<a class="graphic graphic_figure graphicRef81897" href="/z/d/graphic/81897.html" rel="external">figure 1</a>). However, the response in the left lateral segments is important since segment IV would be resected and hence will not contribute to the FLR. Embolization of the segment IV portal vein branch along with the right portal vein (ie, extended embolization) was first reported in 2000 as right trisegment embolization [<a href="#rid82">82</a>]. If an ipsilateral approach to PVE is used, then segment IV embolization should be done first before right PVE; on the other hand, with a contralateral approach, the right PVE is done first before segment IV embolization. It is also essential to embolize the segment IV branches if segment IV is tumor bearing. Rarely, a left trisegment embolization, which includes embolization of the left main portal vein and the right anterior portal vein, may be indicated if the right posterior segment volume is deemed inadequate [<a href="#rid83">83</a>].</p><p>There is evidence to suggest that with extended embolization, the rate and absolute increase in volume of segments II and III would be greater [<a href="#rid82">82,84</a>]. One study found an increase in FLR with extended embolization compared with standard right PVE (50 versus 31 percent), while another study similarly found double the response rate with extended embolization (percent FLR hypertrophy: 54 percent versus 26 percent) [<a href="#rid82">82,84</a>]. However, not all studies have found an advantage of extended embolization, which is technically more demanding and risks injury to the FLR [<a href="#rid85">85</a>]. No strong recommendations can be made, and the choice will depend upon available local expertise. </p><p class="headingAnchor" id="H3807874099"><span class="h2">Potential acceleration of tumor growth</span><span class="headingEndMark"> — </span>Approximately one sixth to one third of patients who undergo PVE for colorectal liver metastasis will suffer disease progression, making them unresectable [<a href="#rid86">86</a>]. There is a concern that at least part of this may be an effect of PVE itself. However, tumor growth may not always be the case, as tumor regression after PVE is also known to occur when PVE is preceded by chemotherapy [<a href="#rid34">34,87</a>].</p><p>PVE appears to accelerate tumor growth [<a href="#rid88">88-92</a>]. One study quantified tumor growth rate after PVE at 0.36 cc/day, which was higher than the 0.05 cc/day found in controls [<a href="#rid91">91</a>]. In colorectal metastasis, tumor growth tends to be similar in the embolized and nonembolized lobes [<a href="#rid34">34,86,87</a>]. Tumor growth rate acceleration in hepatocellular carcinoma is higher at 2.65-fold compared with cholangiocarcinoma at 1.16-fold [<a href="#rid90">90</a>]. A long gap between the last cycle of chemotherapy and PVE, as well as an initial nonresponse to chemotherapy, increases the risk of accelerated tumor growth [<a href="#rid34">34,92</a>].</p><p class="headingAnchor" id="H1174457334"><span class="h2">Ongoing neoadjuvant chemotherapy post-PVE</span><span class="headingEndMark"> — </span>For patients undergoing neoadjuvant chemotherapy prior to hepatic resection, we recommend continuing the chemotherapy following PVE.</p><p>Neoadjuvant chemotherapy is a commonly used strategy in managing initially unresectable or borderline resectable colorectal cancer liver metastasis, but it may also be applicable in selected patients with hilar cholangiocarcinoma. (See  <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Patients undergoing preoperative portal vein embolization'</a>.)</p><p>Whether neoadjuvant chemotherapy should be continued or stopped after PVE is controversial. Stopping chemotherapy after PVE while awaiting hypertrophy for four to six weeks may increase the risk of tumor progression. However, there is some concern that continuing chemotherapy may retard the hypertrophic response to PVE; such an effect has been observed with liver regeneration after liver resection [<a href="#rid93">93-95</a>]. However, this phenomenon may be less pronounced with PVE, and the evidence in fact supports an overall benefit from chemotherapy post-PVE. In a small study of 15 patients, hypertrophy did occur post-PVE despite the continuation of chemotherapy, albeit to a slightly lesser extent [<a href="#rid96">96</a>]. Larger studies have similarly shown no negative effect on the hypertrophic response [<a href="#rid24">24,33,97</a>]. More importantly, in a study of 208 lesions in 64 patients with colorectal liver metastasis, there was a significantly lower rate of tumor progression in patients who received post-PVE chemotherapy compared with those who did not, and continuing chemotherapy post-PVE was independently associated with prolonged long-term survival [<a href="#rid86">86</a>]. </p><p class="headingAnchor" id="H14275846"><span class="h2">Postresection regeneration</span><span class="headingEndMark"> — </span>There has been a concern that PVE may exhaust the regenerative capacity of the liver, and this may lead to inadequate regeneration after liver resection. However, PVE does not appear to adversely affect regeneration of liver after resection. In a small study, the liver regenerated to the same extent (ie, to 80 percent of its original volume) in patients who had PVE as with those who did not have a PVE [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/15094.html" rel="external">"Overview of hepatic resection", section on 'Liver function and regeneration after resection'</a>.)</p><p class="headingAnchor" id="H1401867828"><span class="h1">DISEASE-SPECIFIC OUTCOMES</span><span class="headingEndMark"> — </span>Preoperative portal vein embolization (PVE) allows potentially curative liver resection in patients with an inadequate future liver remnant (FLR). Prior to PVE, all of these patients would otherwise have been candidates for only palliative treatment.<strong> </strong>In general, approximately 70 to 80 percent of patients who undergo PVE ultimately undergo resective surgery [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H4180216878"><span class="h2">Hepatocellular carcinoma</span><span class="headingEndMark"> — </span>Resection for hepatocellular carcinoma (HCC) differs from other cancers because HCC often occurs in a setting of chronic liver disease. PVE is indicated only for well-compensated patients (Child A) with an acceptable hepatic functional reserve (<a class="drug drug_general" data-topicid="8982" href="/z/d/drug information/8982.html" rel="external">indocyanine green</a> retention at 15 minutes &lt;20 percent, FLR 40 to 50 percent) and no other comorbidities that would preclude a major liver resection. (See  <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">"Overview of treatment approaches for hepatocellular carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/2488.html" rel="external">"Surgical resection of hepatocellular carcinoma"</a>.)</p><p>PVE improves resectability rates in HCC, and five-year survival rates after major liver resection post-PVE are at least equivalent and, in many studies, better than in those who did not need PVE [<a href="#rid98">98-102</a>]. As discussed above, sequential transarterial chemoembolization portal vein embolization has volumetric and oncologic advantages in HCC. (See <a class="local">'Sequential TACE-PVE'</a> above.)</p><p class="headingAnchor" id="H2987496299"><span class="h2">Biliary cancer</span><span class="headingEndMark"> — </span>Although technical success rates are high and procedure-related morbidity is low, in the largest review of patients with biliary cancer, approximately 25 percent of patients were unable to undergo liver resection [<a href="#rid83">83</a>]. This dropout rate was higher for gallbladder cancer compared with hilar cholangiocarcinoma (43 versus 17 percent). The five-year survival of resected patients was 39 percent for cholangiocarcinoma and 23 percent for gallbladder cancer, which is commendable given that without PVE all these patients would have otherwise been unresectable [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/z/d/html/15071.html" rel="external">"Surgical resection of localized cholangiocarcinoma"</a>.)</p><p class="headingAnchor" id="H2411566937"><span class="h2">Colorectal cancer liver metastasis</span><span class="headingEndMark"> — </span>PVE for colorectal cancer liver metastases poses some unique challenges. These patients have often undergone neoadjuvant chemotherapy, and they may have some metastasis in the FLR. (See  <a class="medical medical_review" href="/z/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Patients undergoing preoperative portal vein embolization'</a>.) </p><p>Disease burden in the FLR has to be managed before PVE can be applied. In a cohort of patients needing an extended right hepatectomy and presenting with primarily an inadequate FLR alone, PVE improved the rate of resectability from approximately 46 to 79 percent [<a href="#rid35">35</a>].<strong> </strong>The perioperative surgical morbidity and mortality, and long-term survival of patients undergoing major hepatic resection after PVE, are reported to be similar to those of patients who had an adequate FLR at presentation and were not in need of PVE [<a href="#rid35">35,103</a>]. A systematic review identified six studies comparing outcomes of patients undergoing major liver resection for colorectal liver metastases and found no significant differences in postoperative hepatic recurrence for those undergoing liver resection with or without PVE [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H2873096297"><span class="h2">Comparison with other techniques</span></p><p class="headingAnchor" id="H3364996795"><span class="h3">PVE versus portal vein ligation</span><span class="headingEndMark"> — </span>Portal vein ligation (PVL),<strong> </strong>performed by laparotomy or by laparoscopy, is an alternative to PVE [<a href="#rid105">105</a>]. Animal studies suggest that hepatocyte regeneration after PVL is more pronounced than after PVE [<a href="#rid106">106</a>]. A meta-analysis of seven clinical studies involving 218 patients found that there was no significant difference when comparing PVE with PVL in terms of FLR hypertrophy (39 percent with PVE versus 27 percent with PVL) [<a href="#rid107">107</a>]. The morbidity, mortality, and disease progression rates were also similar. </p><p>The current indications for PVL for augmenting FLR are:</p><p class="bulletIndent1"><span class="glyph">●</span>Interventional radiological facilities for PVE are not available</p><p class="bulletIndent1"><span class="glyph">●</span>The patient requires laparoscopy for initial staging</p><p class="bulletIndent1"><span class="glyph">●</span>The liver remnant is judged at laparotomy to be marginal</p><p class="bulletIndent1"><span class="glyph">●</span>The patient will be undergoing a two-staged resection, wherein the first stage involves clearing the FLR of tumor</p><p class="bulletIndent1"><span class="glyph">●</span>PVL is being performed as part of the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure</p><p></p><p class="headingAnchor" id="H3610066597"><span class="h3">PVE versus transarterial radioembolization</span><span class="headingEndMark"> — </span>Transarterial radioembolization<strong> </strong>with 90-Yttrium(<sup>90</sup>Y)-labeled microspheres, also known as selective internal radiotherapy (SIRT), is also known to induce FLR hypertrophy and has the added advantage of preventing tumor progression. However, the magnitude of hypertrophic response is inferior to PVE (29 versus 61 percent) [<a href="#rid108">108</a>].</p><p class="headingAnchor" id="H1504703925"><span class="h3">PVE versus the ALPPS procedure</span><span class="headingEndMark"> — </span>The ALPPS procedure is an alternative to preoperative PVE [<a href="#rid26">26,109-116</a>]. ALPPS is a short-interval, two-staged liver resection [<a href="#rid117">117</a>]. The first stage involves an open right PVL and in situ parenchymal transection in the right trisectionectomy plane [<a href="#rid117">117</a>]. The second stage is performed one to two weeks later and involves a right trisectionectomy. ALPPS produces an accelerated hypertrophy of the functional liver remnant (FLR) in a much shorter time interval than PVE. In a retrospective review, the extrapolated liver growth rate was 11 times higher for ALPPS (34.8 mL/day versus 3 mL/day) [<a href="#rid113">113</a>]. In a case series of patients undergoing ALPPS, the average hypertrophy rate was 85 percent [<a href="#rid114">114</a>]. </p><p>ALPPS is performed only in specialist high-volume centers. In most centers, for patients with an inadequate FLR, preoperative PVE remains the preferred technique [<a href="#rid26">26</a>]. This view may change or be redefined in future as the expertise for ALPPS becomes more widely available. Typical drivers for ALPPS are the improved hypertrophy rates and a higher proportion of patients completing the two-staged treatment; however, the patient is exposed to additional operative risk [<a href="#rid115">115,116</a>]. Salvage ALPPS may have a role in the treatment of patients who do not show an adequate hypertrophy response to preoperative PVE. The LIGRO trial, a multicenter Scandinavian study, is the only randomized trial that has compared ALPPS head-to-head with a two-stage hepatectomy (TSH) where PVE was a component of TSH [<a href="#rid118">118</a>]. The resection rate for the ALPPS group was significantly higher compared with TSH (92 versus 57 percent) among 97 patients with colorectal liver metastasis. Among the 13 patients in the TSH arm who failed to achieve an FLR of 30 percent after PVE, 12 were successfully treated with ALPPS. When indicated, ALPPS should be performed at hepatobiliary centers of excellence that have experience with ALPPS. </p><p class="headingAnchor" id="H3494975645"><span class="h1">MORBIDITY AND MORTALITY</span><span class="headingEndMark"> — </span>Preoperative portal vein embolization (PVE) is overall well tolerated. In a systematic review that included 29 studies reporting on complications after preoperative PVE, the mortality rate was 0.1 percent [<a href="#rid80">80</a>]. The two deaths that followed PVE were due to late septic shock from cholangiolitic abscess, which may be attributed to PVE, and late pulmonary embolism. </p><p>Major complications are uncommon (2 to 3 percent) and include portal vein thrombosis, embolization of nontarget vessels, infection, bile leak, hemobilia, pseudoaneurysm, arteriovenous fistula, arterioportal shunt, liver hematoma, and pneumothorax [<a href="#rid80">80,119-121</a>]. Variceal bleeding from rise in portal pressure has also been reported [<a href="#rid119">119</a>].</p><p>Minor complications, such as fever and ill-defined abdominal discomfort with or without accompanying elevation of transaminases, are fairly common and self-limited, occurring in approximately 20 to 30 percent of patients. Transaminases peak at less than three times the normal values by post-PVE day 3 and return to baseline by 10 days. There may be a mild increase in bilirubin, but albumin and prothrombin time are not usually affected [<a href="#rid4">4</a>]. Ileus and vomiting are uncommon (1 to 2 percent) [<a href="#rid80">80</a>]. </p><p>Technical failures occur in only 0.4 percent. The dropout rate after PVE is approximately 25 percent for various reasons such as disease progression and inadequate hypertrophy, which occurs in approximately 3 percent [<a href="#rid80">80</a>]. </p><p class="headingAnchor" id="H1338958162"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preoperative portal vein embolization</strong> – Preoperative portal vein embolization (PVE) is the elective obliteration of portal blood flow to a selected portion of the liver a few weeks prior to planned major liver resection. PVE elicits a hypertrophic physiologic response in the nonembolized portion augmenting the volume and potentially the function of the future liver remnant (FLR) to a safe threshold to permit potentially curative liver resection. (See <a class="local">'Introduction'</a> above and <a class="local">'Mechanism and physiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physiology</strong> – Preoperative PVE causes a modest increase in the standardized FLR in the range of 8 to 13 percent over a relatively short time of four to six weeks. The absolute FLR percentage increase is between 40 and 60 percent of the baseline FLR volume. (See <a class="local">'Mechanism and physiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient selection</strong> – For patients with a marginal predicted FLR that precludes an otherwise potentially curative hepatectomy, we suggest preoperative PVE, rather than no hepatic resection or an alternative procedure (eg, portal vein ligation [PVL], associating liver partition and portal vein ligation for staged hepatectomy [ALPPS]), prior to hepatic resection provided there are no contraindications to the PVE (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Preoperative PVE is well tolerated and has a more favorable safety profile compared with available alternative techniques. (See <a class="local">'Comparison with other techniques'</a> above and <a class="local">'Disease-specific outcomes'</a> above and <a class="local">'Contraindications'</a> above.) </p><p></p><p class="bulletIndent1">Preoperative portal vein embolization is indicated for a predicted future liver remnant that is (see <a class="local">'Patient selection'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>&lt;20 percent in a normal liver </p><p class="bulletIndent2"><span class="glyph">•</span>&lt;30 percent in the context of cholestasis/hepatitis/chemotherapy</p><p class="bulletIndent2"><span class="glyph">•</span>&lt;40 percent in Child A cirrhosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of hepatic resection</strong> – Although the timing varies, hepatic surgeons generally wait three to six weeks post-PVE before undertaking hepatic resection. Approximately 70 to 80 percent of patients who undergo preoperative PVE eventually undergo successful liver resection. In properly selected patients, resectability rates are increased and the incidence of post-hepatectomy liver failure is decreased. (See <a class="local">'Timing of resection after PVE'</a> above and <a class="local">'Disease-specific outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Techniques</strong> – Preoperative PVE is typically performed via a percutaneous transhepatic approach in an interventional suite under conscious sedation with local anesthesia. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When an extended right hepatectomy is planned, then extended embolization to include segment IV branches of the portal vein should be performed if technical expertise is available. An open surgical approach may be used if laparotomy is indicated for another purpose. (See <a class="local">'Techniques'</a> above and <a class="local">'Extended PVE'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjunctive techniques to PVE include transarterial chemoembolization (TACE), concomitant segmental arterial ligation, hepatic vein embolization, and stem cell transplantation. For patients with hepatocellular carcinoma, sequential TACE-PVE has volumetric as well as survival benefits. (See <a class="local">'Adjunctive techniques'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Abdalla EK, Adam R, Bilchik AJ, et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006; 13:1271.</a></li><li><a class="nounderline abstract_t">Dixon E, Abdalla E, Schwarz RE, Vauthey JN. AHPBA/SSO/SSAT sponsored Consensus Conference on Multidisciplinary Treatment of Hepatocellular Carcinoma. HPB (Oxford) 2010; 12:287.</a></li><li><a class="nounderline abstract_t">Ribero D, Chun YS, Vauthey JN. Standardized liver volumetry for portal vein embolization. Semin Intervent Radiol 2008; 25:104.</a></li><li><a class="nounderline abstract_t">Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001; 88:165.</a></li><li><a class="nounderline abstract_t">Imamura H, Shimada R, Kubota M, et al. Preoperative portal vein embolization: an audit of 84 patients. Hepatology 1999; 29:1099.</a></li><li><a class="nounderline abstract_t">Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg 2008; 247:49.</a></li><li><a class="nounderline abstract_t">Yoo H, Kim JH, Ko GY, et al. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma. Ann Surg Oncol 2011; 18:1251.</a></li><li><a class="nounderline abstract_t">May BJ, Talenfeld AD, Madoff DC. Update on portal vein embolization: evidence-based outcomes, controversies, and novel strategies. J Vasc Interv Radiol 2013; 24:241.</a></li><li><a class="nounderline abstract_t">Mortensen KE, Revhaug A. Liver regeneration in surgical animal models - a historical perspective and clinical implications. Eur Surg Res 2011; 46:1.</a></li><li><a class="nounderline abstract_t">Ribero D, Abdalla EK, Madoff DC, et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007; 94:1386.</a></li><li><a class="nounderline abstract_t">Sumiyoshi T, Shima Y, Tokorodani R, et al. CT/99mTc-GSA SPECT fusion images demonstrate functional differences between the liver lobes. World J Gastroenterol 2013; 19:3217.</a></li><li><a class="nounderline abstract_t">Shoup M, Gonen M, D'Angelica M, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 2003; 7:325.</a></li><li><a class="nounderline abstract_t">Vauthey JN, Abdalla EK, Doherty DA, et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl 2002; 8:233.</a></li><li><a class="nounderline abstract_t">Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl 2005; 11:1481.</a></li><li><a class="nounderline abstract_t">Hirai I, Kimura W, Fuse A, et al. Evaluation of preoperative portal embolization for safe hepatectomy, with special reference to assessment of nonembolized lobe function with 99mTc-GSA SPECT scintigraphy. Surgery 2003; 133:495.</a></li><li><a class="nounderline abstract_t">Cieslak KP, Runge JH, Heger M, et al. New perspectives in the assessment of future remnant liver. Dig Surg 2014; 31:255.</a></li><li><a class="nounderline abstract_t">Uesaka K, Nimura Y, Nagino M. Changes in hepatic lobar function after right portal vein embolization. An appraisal by biliary indocyanine green excretion. Ann Surg 1996; 223:77.</a></li><li><a class="nounderline abstract_t">Rous P, Larimore LD. RELATION OF THE PORTAL BLOOD TO LIVER MAINTENANCE : A DEMONSTRATION OF LIVER ATROPHY CONDITIONAL ON COMPENSATION. J Exp Med 1920; 31:609.</a></li><li><a class="nounderline abstract_t">HONJO I, KOZAKA S. EXTENSIVE RESECTION OF THE LIVER IN TWO STAGES. Rev Int Hepatol 1965; 15:309.</a></li><li><a class="nounderline abstract_t">Makuuchi M, Takayasu K, Takuma T. Transcatheter embolization of the portal venous branch for patients receiving extended lobectomy due to the bile duct carcinoma. J Jpn Surg Assoc 1984; 45:1558.</a></li><li><a class="nounderline abstract_t">Goto Y, Nagino M, Nimura Y. Doppler estimation of portal blood flow after percutaneous transhepatic portal vein embolization. Ann Surg 1998; 228:209.</a></li><li><a class="nounderline abstract_t">Michalopoulos GK. Liver regeneration. J Cell Physiol 2007; 213:286.</a></li><li><a class="nounderline abstract_t">Denys AL, Abehsera M, Leloutre B, et al. Intrahepatic hemodynamic changes following portal vein embolization: a prospective Doppler study. Eur Radiol 2000; 10:1703.</a></li><li><a class="nounderline abstract_t">Goéré D, Farges O, Leporrier J, et al. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg 2006; 10:365.</a></li><li><a class="nounderline abstract_t">Leung U, Simpson AL, Araujo RL, et al. Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure. J Am Coll Surg 2014; 219:620.</a></li><li><a class="nounderline abstract_t">Shindoh J, Vauthey JN, Zimmitti G, et al. Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach. J Am Coll Surg 2013; 217:126.</a></li><li><a class="nounderline abstract_t">Kohno S, Isoda H, Ono A, et al. Portal Vein Embolization: Radiological Findings Predicting Future Liver Remnant Hypertrophy. AJR Am J Roentgenol 2020; 214:687.</a></li><li><a class="nounderline abstract_t">Corrêa D, Schwartz L, Jarnagin WR, et al. Kinetics of liver volume changes in the first year after portal vein embolization. Arch Surg 2010; 145:351.</a></li><li><a class="nounderline abstract_t">Nagino M, Nimura Y, Kamiya J, et al. Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization. Hepatology 1995; 21:434.</a></li><li><a class="nounderline abstract_t">Shimamura T, Nakajima Y, Une Y, et al. Efficacy and safety of preoperative percutaneous transhepatic portal embolization with absolute ethanol: a clinical study. Surgery 1997; 121:135.</a></li><li><a class="nounderline abstract_t">Sturesson C, Keussen I, Tranberg KG. Prolonged chemotherapy impairs liver regeneration after portal vein occlusion - an audit of 26 patients. Eur J Surg Oncol 2010; 36:358.</a></li><li><a class="nounderline abstract_t">de Baere T, Teriitehau C, Deschamps F, et al. Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization. Ann Surg Oncol 2010; 17:2081.</a></li><li><a class="nounderline abstract_t">Covey AM, Brown KT, Jarnagin WR, et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 2008; 247:451.</a></li><li><a class="nounderline abstract_t">Spelt L, Sparrelid E, Isaksson B, et al. Tumour growth after portal vein embolization with pre-procedural chemotherapy for colorectal liver metastases. HPB (Oxford) 2015; 17:529.</a></li><li><a class="nounderline abstract_t">Shindoh J, Tzeng CW, Aloia TA, et al. Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. Br J Surg 2013; 100:1777.</a></li><li><a class="nounderline abstract_t">Shindoh J, D Tzeng CW, Vauthey JN. Portal vein embolization for hepatocellular carcinoma. Liver Cancer 2012; 1:159.</a></li><li><a class="nounderline abstract_t">Shindoh J, Truty MJ, Aloia TA, et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 2013; 216:201.</a></li><li><a class="nounderline abstract_t">Ferrero A, Viganò L, Polastri R, et al. Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study. World J Surg 2007; 31:1643.</a></li><li><a class="nounderline abstract_t">Mailey B, Truong C, Artinyan A, et al. Surgical resection of primary and metastatic hepatic malignancies following portal vein embolization. J Surg Oncol 2009; 100:184.</a></li><li><a class="nounderline abstract_t">van den Esschert JW, de Graaf W, van Lienden KP, et al. Volumetric and functional recovery of the remnant liver after major liver resection with prior portal vein embolization : recovery after PVE and liver resection. J Gastrointest Surg 2009; 13:1464.</a></li><li><a class="nounderline abstract_t">Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94:274.</a></li><li><a class="nounderline abstract_t">Kuo SC, Azimi-Tabrizi A, Briggs G, et al. Portal vein embolization prior to major liver resection. ANZ J Surg 2014; 84:341.</a></li><li><a class="nounderline abstract_t">Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003; 237:208.</a></li><li><a class="nounderline abstract_t">Shirabe K, Shimada M, Gion T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 1999; 188:304.</a></li><li><a class="nounderline abstract_t">Ganeshan DM, Szklaruk J. Portal vein embolization: cross-sectional imaging of normal features and complications. AJR Am J Roentgenol 2012; 199:1275.</a></li><li><a class="nounderline abstract_t">Truant S, Oberlin O, Sergent G, et al. Remnant liver volume to body weight ratio &gt; or =0.5%: A new cut-off to estimate postoperative risks after extended resection in noncirrhotic liver. J Am Coll Surg 2007; 204:22.</a></li><li><a class="nounderline abstract_t">de Meijer VE, Kalish BT, Puder M, Ijzermans JN. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg 2010; 97:1331.</a></li><li><a class="nounderline abstract_t">Kubota K, Makuuchi M, Kusaka K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997; 26:1176.</a></li><li><a class="nounderline abstract_t">Lin XJ, Yang J, Chen XB, et al. The critical value of remnant liver volume-to-body weight ratio to estimate posthepatectomy liver failure in cirrhotic patients. J Surg Res 2014; 188:489.</a></li><li><a class="nounderline abstract_t">Vauthey JN, Chaoui A, Do KA, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 2000; 127:512.</a></li><li><a class="nounderline abstract_t">Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002; 137:675.</a></li><li><a class="nounderline abstract_t">Kishi Y, Abdalla EK, Chun YS, et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg 2009; 250:540.</a></li><li><a class="nounderline abstract_t">She WH, Chok KSh. Strategies to increase the resectability of hepatocellular carcinoma. World J Hepatol 2015; 7:2147.</a></li><li><a class="nounderline abstract_t">Madoff DC, Gaba RC, Weber CN, et al. Portal Venous Interventions: State of the Art. Radiology 2016; 278:333.</a></li><li><a class="nounderline abstract_t">Perarnau JM, Daradkeh S, Johann M, et al. Transjugular preoperative portal embolization (TJPE) a pilot study. Hepatogastroenterology 2003; 50:610.</a></li><li><a class="nounderline abstract_t">Ko HK, Ko GY, Sung KB, et al. Portal Vein Embolization via Percutaneous Transsplenic Access prior to Major Hepatectomy for Patients with Insufficient Future Liver Remnant. J Vasc Interv Radiol 2016; 27:981.</a></li><li><a class="nounderline abstract_t">Avritscher R, de Baere T, Murthy R, et al. Percutaneous transhepatic portal vein embolization: rationale, technique, and outcomes. Semin Intervent Radiol 2008; 25:132.</a></li><li><a class="nounderline abstract_t">Kinoshita H, Sakai K, Hirohashi K, et al. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg 1986; 10:803.</a></li><li><a class="nounderline abstract_t">Nagino M, Nimura Y, Kamiya J, et al. Selective percutaneous transhepatic embolization of the portal vein in preparation for extensive liver resection: the ipsilateral approach. Radiology 1996; 200:559.</a></li><li><a class="nounderline abstract_t">Fischman AM, Ward TJ, Horn JC, et al. Portal vein embolization before right hepatectomy or extended right hepatectomy using sodium tetradecyl sulfate foam: technique and initial results. J Vasc Interv Radiol 2014; 25:1045.</a></li><li><a class="nounderline abstract_t">Madoff DC, Abdalla EK, Gupta S, et al. Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils. J Vasc Interv Radiol 2005; 16:215.</a></li><li><a class="nounderline abstract_t">Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007; 11:860.</a></li><li><a class="nounderline abstract_t">Aoki T, Imamura H, Hasegawa K, et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 2004; 139:766.</a></li><li><a class="nounderline abstract_t">Ogata S, Belghiti J, Farges O, et al. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg 2006; 93:1091.</a></li><li><a class="nounderline abstract_t">Terasawa M, Allard MA, Golse N, et al. Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization alone before major hepatectomy for patients with large hepatocellular carcinoma: An intent-to-treat analysis. Surgery 2020; 167:425.</a></li><li><a class="nounderline abstract_t">Tustumi F, Ernani L, Coelho FF, et al. Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford) 2018; 20:1109.</a></li><li><a class="nounderline abstract_t">Dupré A, Hitier M, Peyrat P, et al. Associating portal embolization and artery ligation to induce rapid liver regeneration in staged hepatectomy. Br J Surg 2015; 102:1541.</a></li><li><a class="nounderline abstract_t">Hwang S, Lee SG, Ko GY, et al. Sequential preoperative ipsilateral hepatic vein embolization after portal vein embolization to induce further liver regeneration in patients with hepatobiliary malignancy. Ann Surg 2009; 249:608.</a></li><li><a class="nounderline abstract_t">Munene G, Parker RD, Larrigan J, et al. Sequential preoperative hepatic vein embolization after portal vein embolization for extended left hepatectomy in colorectal liver metastases. World J Surg Oncol 2013; 11:134.</a></li><li><a class="nounderline abstract_t">Dueland S, Yaqub S, Syversveen T, et al. Survival Outcomes After Portal Vein Embolization and Liver Resection Compared With Liver Transplant for Patients With Extensive Colorectal Cancer Liver Metastases. JAMA Surg 2021; 156:550.</a></li><li><a class="nounderline abstract_t">Gehling UM, Willems M, Dandri M, et al. Partial hepatectomy induces mobilization of a unique population of haematopoietic progenitor cells in human healthy liver donors. J Hepatol 2005; 43:845.</a></li><li><a class="nounderline abstract_t">am Esch JS 2nd, Knoefel WT, Klein M, et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 2005; 23:463.</a></li><li><a class="nounderline abstract_t">Fürst G, Schulte am Esch J, Poll LW, et al. Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience. Radiology 2007; 243:171.</a></li><li><a class="nounderline abstract_t">am Esch JS, Schmelzle M, Fürst G, et al. Infusion of CD133+ bone marrow-derived stem cells after selective portal vein embolization enhances functional hepatic reserves after extended right hepatectomy: a retrospective single-center study. Ann Surg 2012; 255:79.</a></li><li><a class="nounderline abstract_t">Beppu T, Nitta H, Hayashi H, et al. Effect of branched-chain amino acid supplementation on functional liver regeneration in patients undergoing portal vein embolization and sequential hepatectomy: a randomized controlled trial. J Gastroenterol 2015; 50:1197.</a></li><li><a class="nounderline abstract_t">Olthof PB, Huisman F, van Golen RF, et al. Use of an absorbable embolization material for reversible portal vein embolization in an experimental model. Br J Surg 2016; 103:1306.</a></li><li><a class="nounderline abstract_t">Madoff DC, Gupta S, Pillsbury EP, et al. Transarterial versus transhepatic portal vein embolization to induce selective hepatic hypertrophy: a comparative study in swine. J Vasc Interv Radiol 2007; 18:79.</a></li><li><a class="nounderline abstract_t">Smits ML, Vanlangenhove P, Sturm EJ, et al. Transsinusoidal portal vein embolization with ethylene vinyl alcohol copolymer (Onyx): a feasibility study in pigs. Cardiovasc Intervent Radiol 2012; 35:1172.</a></li><li><a class="nounderline abstract_t">Lainas P, Boudechiche L, Osorio A, et al. Liver regeneration and recanalization time course following reversible portal vein embolization. J Hepatol 2008; 49:354.</a></li><li><a class="nounderline abstract_t">van Lienden KP, van den Esschert JW, de Graaf W, et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol 2013; 36:25.</a></li><li><a class="nounderline abstract_t">van Gulik TM, van den Esschert JW, de Graaf W, et al. Controversies in the use of portal vein embolization. Dig Surg 2008; 25:436.</a></li><li><a class="nounderline abstract_t">Nagino M, Kamiya J, Kanai M, et al. Right trisegment portal vein embolization for biliary tract carcinoma: technique and clinical utility. Surgery 2000; 127:155.</a></li><li><a class="nounderline abstract_t">Ebata T, Yokoyama Y, Igami T, et al. Portal vein embolization before extended hepatectomy for biliary cancer: current technique and review of 494 consecutive embolizations. Dig Surg 2012; 29:23.</a></li><li><a class="nounderline abstract_t">Kishi Y, Madoff DC, Abdalla EK, et al. Is embolization of segment 4 portal veins before extended right hepatectomy justified? Surgery 2008; 144:744.</a></li><li><a class="nounderline abstract_t">Capussotti L, Muratore A, Ferrero A, et al. Extension of right portal vein embolization to segment IV portal branches. Arch Surg 2005; 140:1100.</a></li><li><a class="nounderline abstract_t">Fischer C, Melstrom LG, Arnaoutakis D, et al. Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy. JAMA Surg 2013; 148:1103.</a></li><li><a class="nounderline abstract_t">Pommier R, Ronot M, Cauchy F, et al. Colorectal liver metastases growth in the embolized and non-embolized liver after portal vein embolization: influence of initial response to induction chemotherapy. Ann Surg Oncol 2014; 21:3077.</a></li><li><a class="nounderline abstract_t">Elias D, De Baere T, Roche A, et al. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999; 86:784.</a></li><li><a class="nounderline abstract_t">Kokudo N, Tada K, Seki M, et al. Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 2001; 34:267.</a></li><li><a class="nounderline abstract_t">Hayashi S, Baba Y, Ueno K, et al. Acceleration of primary liver tumor growth rate in embolized hepatic lobe after portal vein embolization. Acta Radiol 2007; 48:721.</a></li><li><a class="nounderline abstract_t">Pamecha V, Levene A, Grillo F, et al. Effect of portal vein embolisation on the growth rate of colorectal liver metastases. Br J Cancer 2009; 100:617.</a></li><li><a class="nounderline abstract_t">Simoneau E, Aljiffry M, Salman A, et al. Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases. HPB (Oxford) 2012; 14:461.</a></li><li><a class="nounderline abstract_t">Shindoh J, Tzeng CW, Aloia TA, et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol 2013; 20:2493.</a></li><li><a class="nounderline abstract_t">Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065.</a></li><li><a class="nounderline abstract_t">Sturesson C, Nilsson J, Eriksson S, et al. Limiting factors for liver regeneration after a major hepatic resection for colorectal cancer metastases. HPB (Oxford) 2013; 15:646.</a></li><li><a class="nounderline abstract_t">Beal IK, Anthony S, Papadopoulou A, et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol 2006; 79:473.</a></li><li><a class="nounderline abstract_t">Zorzi D, Chun YS, Madoff DC, et al. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 2008; 15:2765.</a></li><li><a class="nounderline abstract_t">Seo DD, Lee HC, Jang MK, et al. Preoperative portal vein embolization and surgical resection in patients with hepatocellular carcinoma and small future liver remnant volume: comparison with transarterial chemoembolization. Ann Surg Oncol 2007; 14:3501.</a></li><li><a class="nounderline abstract_t">Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg 2000; 232:665.</a></li><li><a class="nounderline abstract_t">Tanaka H, Hirohashi K, Kubo S, et al. Preoperative portal vein embolization improves prognosis after right hepatectomy for hepatocellular carcinoma in patients with impaired hepatic function. Br J Surg 2000; 87:879.</a></li><li><a class="nounderline abstract_t">Wakabayashi H, Ishimura K, Okano K, et al. Is preoperative portal vein embolization effective in improving prognosis after major hepatic resection in patients with advanced-stage hepatocellular carcinoma? Cancer 2001; 92:2384.</a></li><li><a class="nounderline abstract_t">Palavecino M, Chun YS, Madoff DC, et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery 2009; 145:399.</a></li><li><a class="nounderline abstract_t">Ardito F, Vellone M, Barbaro B, et al. Right and extended-right hepatectomies for unilobar colorectal metastases: impact of portal vein embolization on long-term outcome and liver recurrence. Surgery 2013; 153:801.</a></li><li><a class="nounderline abstract_t">Giglio MC, Giakoustidis A, Draz A, et al. Oncological Outcomes of Major Liver Resection Following Portal Vein Embolization: A Systematic Review and Meta-analysis. Ann Surg Oncol 2016; 23:3709.</a></li><li><a class="nounderline abstract_t">Are C, Iacovitti S, Prete F, Crafa FM. Feasibility of laparoscopic portal vein ligation prior to major hepatectomy. HPB (Oxford) 2008; 10:229.</a></li><li><a class="nounderline abstract_t">Furrer K, Tian Y, Pfammatter T, et al. Selective portal vein embolization and ligation trigger different regenerative responses in the rat liver. Hepatology 2008; 47:1615.</a></li><li><a class="nounderline abstract_t">Pandanaboyana S, Bell R, Hidalgo E, et al. A systematic review and meta-analysis of portal vein ligation versus portal vein embolization for elective liver resection. Surgery 2015; 157:690.</a></li><li><a class="nounderline abstract_t">Garlipp B, de Baere T, Damm R, et al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology 2014; 59:1864.</a></li><li><a class="nounderline abstract_t">Oldhafer KJ, Stavrou GA, van Gulik TM, Core Group. ALPPS--Where Do We Stand, Where Do We Go?: Eight Recommendations From the First International Expert Meeting. Ann Surg 2016; 263:839.</a></li><li><a class="nounderline abstract_t">Wicherts DA, Miller R, de Haas RJ, et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 2008; 248:994.</a></li><li><a class="nounderline abstract_t">Torres OJ, Fernandes Ede S, Oliveira CV, et al. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): the Brazilian experience. Arq Bras Cir Dig 2013; 26:40.</a></li><li><a class="nounderline abstract_t">Knoefel WT, Gabor I, Rehders A, et al. In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two-stage liver resection. Br J Surg 2013; 100:388.</a></li><li><a class="nounderline abstract_t">Schadde E, Ardiles V, Slankamenac K, et al. ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis. World J Surg 2014; 38:1510.</a></li><li><a class="nounderline abstract_t">Ielpo B, Caruso R, Ferri V, et al. ALPPS procedure: our experience and state of the art. Hepatogastroenterology 2013; 60:2069.</a></li><li><a class="nounderline abstract_t">Eshmuminov D, Raptis DA, Linecker M, et al. Meta-analysis of associating liver partition with portal vein ligation and portal vein occlusion for two-stage hepatectomy. Br J Surg 2016; 103:1768.</a></li><li><a class="nounderline abstract_t">Liu Y, Yang Y, Gu S, Tang K. A systematic review and meta-analysis of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) versus traditional staged hepatectomy. Medicine (Baltimore) 2019; 98:e15229.</a></li><li><a class="nounderline abstract_t">Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012; 255:405.</a></li><li><a class="nounderline abstract_t">Sandström P, Røsok BI, Sparrelid E, et al. ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial). Ann Surg 2018; 267:833.</a></li><li><a class="nounderline abstract_t">Kodama Y, Shimizu T, Endo H, et al. Complications of percutaneous transhepatic portal vein embolization. J Vasc Interv Radiol 2002; 13:1233.</a></li><li><a class="nounderline abstract_t">Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg 2006; 243:364.</a></li><li><a class="nounderline abstract_t">Di Stefano DR, de Baere T, Denys A, et al. Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients. Radiology 2005; 234:625.</a></li></ol></div><div id="topicVersionRevision">Topic 106477 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16955381" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Improving resectability of hepatic colorectal metastases: expert consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20590900" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : AHPBA/SSO/SSAT sponsored Consensus Conference on Multidisciplinary Treatment of Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21326551" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Standardized liver volumetry for portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11167863" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Portal vein embolization: rationale, technique and future prospects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10094953" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Preoperative portal vein embolization: an audit of 84 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156923" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Preoperative portal vein embolization for major liver resection: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21069467" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization only before major hepatectomy for patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23369559" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Update on portal vein embolization: evidence-based outcomes, controversies, and novel strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21135558" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Liver regeneration in surgical animal models - a historical perspective and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17583900" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23745023" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : CT/99mTc-GSA SPECT fusion images demonstrate functional differences between the liver lobes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654556" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11910568" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Body surface area and body weight predict total liver volume in Western adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16315293" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Changes in liver volume from birth to adulthood: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12773977" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Evaluation of preoperative portal embolization for safe hepatectomy, with special reference to assessment of nonembolized lobe function with 99mTc-GSA SPECT scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25322678" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : New perspectives in the assessment of future remnant liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8554422" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Changes in hepatic lobar function after right portal vein embolization. An appraisal by biliary indocyanine green excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19868417" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : RELATION OF THE PORTAL BLOOD TO LIVER MAINTENANCE : A DEMONSTRATION OF LIVER ATROPHY CONDITIONAL ON COMPENSATION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14329740" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : EXTENSIVE RESECTION OF THE LIVER IN TWO STAGES.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Transcatheter embolization of the portal venous branch for patients receiving extended lobectomy due to the bile duct carcinoma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9712566" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Doppler estimation of portal blood flow after percutaneous transhepatic portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17559071" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Liver regeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11097391" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Intrahepatic hemodynamic changes following portal vein embolization: a prospective Doppler study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16504881" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25158914" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23632095" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31642696" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Portal Vein Embolization: Radiological Findings Predicting Future Liver Remnant Hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20404285" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Kinetics of liver volume changes in the first year after portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7843717" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9037224" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Efficacy and safety of preoperative percutaneous transhepatic portal embolization with absolute ethanol: a clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100648" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prolonged chemotherapy impairs liver regeneration after portal vein occlusion - an audit of 26 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20237856" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18376189" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25726854" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Tumour growth after portal vein embolization with pre-procedural chemotherapy for colorectal liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24227364" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24159580" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Portal vein embolization for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23219349" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17551779" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19572328" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Surgical resection of primary and metastatic hepatic malignancies following portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19475462" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Volumetric and functional recovery of the remnant liver after major liver resection with prior portal vein embolization : recovery after PVE and liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17315288" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23231008" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Portal vein embolization prior to major liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12560779" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Portal vein embolization before right hepatectomy: prospective clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10065820" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169719" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Portal vein embolization: cross-sectional imaging of normal features and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17189109" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Remnant liver volume to body weight ratio&gt;or =0.5%: A new cut-off to estimate postoperative risks after extended resection in noncirrhotic liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20641066" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9362359" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24569034" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The critical value of remnant liver volume-to-body weight ratio to estimate posthepatectomy liver failure in cirrhotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10819059" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12049538" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19730239" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26328026" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Strategies to increase the resectability of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26789601" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Portal Venous Interventions: State of the Art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12828044" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Transjugular preoperative portal embolization (TJPE) a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27234484" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Portal Vein Embolization via Percutaneous Transsplenic Access prior to Major Hepatectomy for Patients with Insufficient Future Liver Remnant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21326554" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Percutaneous transhepatic portal vein embolization: rationale, technique, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3022488" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Preoperative portal vein embolization for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8685357" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Selective percutaneous transhepatic embolization of the portal vein in preparation for extensive liver resection: the ipsilateral approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24657089" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Portal vein embolization before right hepatectomy or extended right hepatectomy using sodium tetradecyl sulfate foam: technique and initial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15713922" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Transhepatic ipsilateral right portal vein embolization extended to segment IV: improving hypertrophy and resection outcomes with spherical particles and coils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17492335" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15249411" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16779884" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31780050" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization alone before major hepatectomy for patients with large hepatocellular carcinoma: An intent-to-treat analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30057123" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26375763" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Associating portal embolization and artery ligation to induce rapid liver regeneration in staged hepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19300228" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sequential preoperative ipsilateral hepatic vein embolization after portal vein embolization to induce further liver regeneration in patients with hepatobiliary malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23758777" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Sequential preoperative hepatic vein embolization after portal vein embolization for extended left hepatectomy in colorectal liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33787838" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Survival Outcomes After Portal Vein Embolization and Liver Resection Compared With Liver Transplant for Patients With Extensive Colorectal Cancer Liver Metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16139387" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Partial hepatectomy induces mobilization of a unique population of haematopoietic progenitor cells in human healthy liver donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15790766" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17312278" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Portal vein embolization and autologous CD133+ bone marrow stem cells for liver regeneration: initial experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22156926" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Infusion of CD133+ bone marrow-derived stem cells after selective portal vein embolization enhances functional hepatic reserves after extended right hepatectomy: a retrospective single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25847401" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effect of branched-chain amino acid supplementation on functional liver regeneration in patients undergoing portal vein embolization and sequential hepatectomy: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27477877" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Use of an absorbable embolization material for reversible portal vein embolization in an experimental model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296708" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Transarterial versus transhepatic portal vein embolization to induce selective hepatic hypertrophy: a comparative study in swine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21979794" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Transsinusoidal portal vein embolization with ethylene vinyl alcohol copolymer (Onyx): a feasibility study in pigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18387688" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Liver regeneration and recanalization time course following reversible portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22806245" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Portal vein embolization before liver resection: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19212116" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Controversies in the use of portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10686980" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Right trisegment portal vein embolization for biliary tract carcinoma: technique and clinical utility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22441616" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Portal vein embolization before extended hepatectomy for biliary cancer: current technique and review of 494 consecutive embolizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19081016" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Is embolization of segment 4 portal veins before extended right hepatectomy justified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16301448" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Extension of right portal vein embolization to segment IV portal branches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24173207" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24743912" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Colorectal liver metastases growth in the embolized and non-embolized liver after portal vein embolization: influence of initial response to induction chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10383579" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11481611" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17729001" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Acceleration of primary liver tumor growth rate in embolized hepatic lobe after portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19209170" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effect of portal vein embolisation on the growth rate of colorectal liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22672548" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Portal vein embolization stimulates tumour growth in patients with colorectal cancer liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23377564" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648507" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23458360" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Limiting factors for liver regeneration after a major hepatic resection for colorectal cancer metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16714748" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18636296" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17899289" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Preoperative portal vein embolization and surgical resection in patients with hepatocellular carcinoma and small future liver remnant volume: comparison with transarterial chemoembolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11066138" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931022" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Preoperative portal vein embolization improves prognosis after right hepatectomy for hepatocellular carcinoma in patients with impaired hepatic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11745294" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Is preoperative portal vein embolization effective in improving prognosis after major hepatic resection in patients with advanced-stage hepatocellular carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19303988" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23701876" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Right and extended-right hepatectomies for unilobar colorectal metastases: impact of portal vein embolization on long-term outcome and liver recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27272106" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Oncological Outcomes of Major Liver Resection Following Portal Vein Embolization: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18806869" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Feasibility of laparoscopic portal vein ligation prior to major hepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18395841" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Selective portal vein embolization and ligation trigger different regenerative responses in the rat liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25704417" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : A systematic review and meta-analysis of portal vein ligation versus portal vein embolization for elective liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24259442" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26756771" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : ALPPS--Where Do We Stand, Where Do We Go?: Eight Recommendations From the First International Expert Meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092344" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23702869" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): the Brazilian experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23124776" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two-stage liver resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24748319" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24719949" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : ALPPS procedure: our experience and state of the art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27633328" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Meta-analysis of associating liver partition with portal vein ligation and portal vein occlusion for two-stage hepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30985727" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : A systematic review and meta-analysis of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) versus traditional staged hepatectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22330038" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28902669" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12471187" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Complications of percutaneous transhepatic portal vein embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495702" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15591428" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Preoperative percutaneous portal vein embolization: evaluation of adverse events in 188 patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
